Browse the evidence

Genotype-matched dietary interventions (low-fat vs. low-carbohydrate) may not consistently predict weight loss success in postmenopausal women compared to general overweight populations.

Do not rely solely on genetic testing to dictate whether you should eat low-fat or low-carb. Focus on sustainable dietary patterns like DASH or MED, as genotype matching has not consistently proven superior for weight loss in recent large studies.

Chronic consumption of monosodium glutamate (MSG) is associated with increased risk of obesity and weight gain, primarily through mechanisms involving hypothalamic damage, leptin resistance, and altered gut microbiota.

While MSG is legally safe, emerging research suggests high chronic intake, especially from processed foods with hidden MSG, may disrupt appetite regulation and contribute to weight gain. To mitigate potential risk, prioritize whole foods and check labels for hidden sources like hydrolyzed protein or yeast extract.

Increasing protein intake from a moderate level (1.8 g/kg/day) to a high level (2.9 g/kg/day) does not provide additional satiety benefits for resistance-trained individuals in a caloric deficit.

If you are training and cutting calories, aim for about 1.8g of protein per kg of body weight. Going higher to 2.9g won't help you feel fuller or fight hunger any better, so don't stress about forcing extra protein just for satiety reasons.

Long-acting GLP-1 receptor agonists (GLP-1RAs) attenuate obesity and reverse leptin resistance by reshaping gut microbiota to increase Akkermansia muciniphila, which produces inosine to activate the macrophage A2A pathway, thereby reducing adipocyte leptin levels.

This research suggests that GLP-1 medications (like semaglutide or liraglutide) may work partly by changing your gut bacteria to produce a molecule called inosine. This molecule helps reduce leptin, a hormone that regulates fat storage. While you cannot directly control this pathway, maintaining gut health through diet may support the effectiveness of these medications.

Specific additives found in UPFs, such as carrageenan and endocrine-disrupting chemicals like Bisphenol-A (BPA) and acrylamide, contribute to T2DM risk through mechanisms involving insulin resistance, inflammation, and gut microbiota alteration.

Be aware that certain additives (carrageenan, specific emulsifiers) and packaging-derived chemicals (BPA, phthalates) in UPFs may promote insulin resistance and inflammation. Reducing intake of products containing these specific ingredients, especially sugary beverages and processed meats, may lower T2DM risk.

Slimming product advertisements in Switzerland make false promises of rapid weight loss (300g–1kg daily) without lifestyle changes, exploiting legislative voids to generate significant revenue.

Be skeptical of any slimming product advertising rapid weight loss (e.g., >1kg/week) without lifestyle changes. These claims are legally and scientifically unsupported in Switzerland and likely elsewhere. Focus on evidence-based strategies rather than supplements marketed with 'natural' or 'scientific' buzzwords.

Tirzepatide may allow some patients with moderate OSA (AHI 15-30) who are asymptomatic (except for snoring) to discontinue CPAP, as the benefit of CPAP in this subgroup is unclear.

If you have moderate OSA and are not sleepy (only snoring), ask your doctor if you can try tirzepatide alone. Since CPAP's benefit in asymptomatic moderate OSA is unclear, tirzepatide might resolve your OPA without the need for a machine. This requires monitoring and may not be suitable for everyone.

Adding 250 mg of protease enzymes (ProHydrolase) to 26 g of whey protein post-resistance exercise does not increase the total amino acid exposure (AUC) or anabolic signaling (mTOR/p70S6K phosphorylation) compared to consuming 26 g of whey protein alone in trained males.

If you are taking whey protein after your workout, adding a specific protease enzyme blend (like ProHydrolase) does not provide any additional benefit for muscle protein synthesis or total amino acid absorption compared to taking whey protein by itself. You do not need to buy specialized enzyme-enhanced proteins to maximize your results; standard whey protein is sufficient.

GLP-1 receptor agonists may have disease-modifying effects on osteoarthritis and osteoporosis by reducing inflammation and promoting bone formation.

If you have joint pain or weak bones, ask your doctor if your GLP-1 medication might offer extra protection. While weight loss is the main benefit, these drugs may also reduce inflammation in joints and help maintain bone density.

GLP-1 receptor agonists (GLP-1RAs) reduce the risk of hepatic decompensation events in patients with type 2 diabetes and compensated cirrhosis compared to DPP4 inhibitors and sulfonylureas.

If you have type 2 diabetes and compensated cirrhosis, GLP-1 receptor agonists may help reduce your risk of serious liver complications like fluid buildup or bleeding compared to other common diabetes medications. Discuss the benefits and risks with your doctor.

In obese or overweight individuals with low glucose effectiveness (Sg), subclinical reactive hypoglycemia (SRH) acts as a biological driver for frequent snacking, creating a vicious cycle that promotes obesity.

If you struggle to stop snacking despite gaining weight, it may not be a failure of willpower but a metabolic response. Specifically, if you have low glucose effectiveness, your body may drop into subclinical hypoglycemia after meals, triggering intense hunger to protect your brain. To break this cycle, focus on lifestyle factors that improve glucose effectiveness, such as regular walking (≥8000 steps/day) and reducing high-fat/sugar intake, rather than relying solely on willpower to resist snacks.

Menstrual cycle symptoms are widespread and severe in resistance-trained athletes, with 92% reporting symptoms and 76% reporting cramps, yet MC irregularities are not more common than in the general exercising population.

Expect menstrual symptoms like cramps and fatigue to be common (92% prevalence) regardless of your competitive level. However, do not assume your resistance training is causing irregular periods; your cycle regularity is likely similar to other women. Focus on managing the high prevalence of symptoms (like cramps and fatigue) through tracking and potentially hormonal or lifestyle interventions.

GLP-1 receptor agonists (GLP-1 RAs) reduce alcohol consumption and craving in patients with Alcohol Use Disorder (AUD) by modulating the mesolimbic dopamine reward pathway.

If you have AUD, especially if you also have obesity or Type 2 Diabetes, GLP-1 medications (like Semaglutide) may help reduce your alcohol intake and cravings by affecting brain reward pathways. This is an emerging off-label use, so discuss it with your doctor, particularly if standard treatments have failed or caused side effects.

Preoperative factors such as duration of diabetes, high HbA1c, and insulin use predict failure of T2DM remission after bariatric surgery.

If you have had diabetes for a long time or require high doses of insulin, your chances of complete remission after surgery are lower. This highlights the importance of considering surgery earlier in the disease course, before beta-cell function is severely compromised.

GLP-1 agonists do not directly cause acne vulgaris; reported acne-like symptoms are likely injection-site hypersensitivity reactions or secondary to weight-loss-induced hormonal changes (e.g., IGF-1 increases).

If you are using a GLP-1 agonist and develop acne, it is likely not the drug directly attacking your skin. Instead, the weight loss you are experiencing may trigger hormonal shifts (like increased IGF-1) that worsen acne. Alternatively, any lumps you see are likely injection-site reactions, not acne. Consult your doctor to distinguish between these causes.

GLP-1 receptor agonists (GLP-1 RAs) reduce systemic and intestinal inflammation in Inflammatory Bowel Disease (IBD) by modulating immune cell signaling, enhancing the intestinal epithelial barrier, and improving gut microbiota composition.

If you have IBD and are considering GLP-1 medications (like Semaglutide or Liraglutide) for weight loss or diabetes, current evidence suggests they may actually help your gut health by reducing inflammation and lowering the risk of surgery. Start with a low dose and titrate slowly to manage nausea. Monitor your symptoms, but know that studies show these drugs do not increase the risk of IBD flares or hospitalizations compared to other diabetes medications. If you are underweight, discuss this carefully with your doctor, as the primary benefit in obese IBD patients is well-documented.

Long-term use of incretin agonists shows attenuated efficacy over time, with weight loss and HbA1c improvements diminishing significantly in the 3rd to 7th year of treatment.

If you are on incretin medication for several years, you may notice that the weight loss and blood sugar improvements slow down or plateau. This is a known biological response (tachyphylaxis). It does not mean the drug has stopped working entirely, but it may require dose adjustments or intensified lifestyle efforts to maintain benefits.

Solo biofragmentable magnetic duodenoileostomy (MagDI) creates a partial intestinal bypass that significantly reduces body weight and improves type 2 diabetes markers in patients with mild obesity (BMI 30-35).

This paper describes a new, minimally invasive surgical option for people with mild obesity (BMI 30-35) and type 2 diabetes. Instead of removing part of the stomach, doctors use magnets to connect the upper small intestine (duodenum) to the lower small intestine (ileum). This creates a partial bypass that helps you lose weight and control blood sugar without major surgery or permanent implants. The magnets dissolve and pass naturally after about 3 weeks. While promising, this is a new procedure with limited long-term data, so it should be considered carefully with a specialist.

Tirzepatide may reduce the risk of atherosclerosis progression through lipid-lowering, anti-inflammatory, and improved insulin sensitivity mechanisms, offering cardioprotective benefits beyond glycemic control.

Tirzepatide not only lowers blood sugar and helps with weight loss but may also protect your heart and blood vessels by reducing inflammation and improving lipid levels. This is especially important if you have diabetes and heart disease.

Gastric pouch resizing (GPR) for Roux-en-Y gastric bypass (RYGB) failure yields a 53% success rate at 10 years, defined as >50% excess weight loss (%EWL) and/or resolution of comorbidities, despite a 47% failure rate characterized by significant weight regain.

If you have regained weight after a Roux-en-Y gastric bypass, it may be due to your stomach pouch stretching. Gastric pouch resizing is a surgical option that can help restore restriction. However, be aware that nearly half of patients experience significant weight regain within 10 years. This procedure is most effective for those with a specifically dilated pouch and may help resolve other health issues like GERD, but it is not a guaranteed long-term fix for everyone.

Collegiate student-athletes have low knowledge of nutritional supplements and third-party-tested (TPT) logos, and this lack of recognition does not correlate with their actual use of TPT supplements.

If you are a collegiate athlete, do not assume that recognizing a third-party testing logo means you are using safe supplements. The study shows that knowing the logo does not predict whether you actually use TPT products. Your overall knowledge of supplements is likely lower than you think (median 33% correct). To mitigate doping risk, do not rely on logos alone. Verify every specific product batch on the testing organization's official website, regardless of whether you received nutritional counseling from your athletic department.

Native gut-produced GLP-1 exerts central anorectic effects via a neuroendocrine signaling mechanism involving the portal vein and vagal afferent nerves, without entering the brain.

Your body naturally produces GLP-1 after eating, which signals fullness to your brain via the vagus nerve. This is a fast, efficient system that doesn't require the hormone to cross into the brain tissue, explaining why synthetic GLP-1 drugs mimic this natural process effectively.

Cultural evolution, specifically the adoption of cooking and processed foods, provided the necessary energy surplus to drive human brain expansion and physiological reconditioning, establishing an evolutionary trajectory that predisposes modern humans to obesity in obesogenic environments.

Understand that your body's drive to store fat is an evolutionary adaptation to a high-energy niche created by cooking and tool use, not a moral failing. In a modern environment with unlimited processed food, this adaptation becomes maladaptive. The solution requires changing the environment (non-obesogenic) rather than just relying on willpower.

The consumption of cooked and processed foods enhances nutrient bioavailability (e.g., glucose, DHA, antioxidants) and reduces foraging time, which was a prerequisite for the metabolic cost of maintaining a large human brain.

Cooking is not just a convenience but a biological necessity for human brain function. It unlocks nutrients like DHA and antioxidants that are harder to get from raw food. However, modern ultra-processed foods are different from home-cooked food and contribute to obesity.